Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
On July 27, 2021, Amgen announced that it will acquire Bay area-based Teneobio, a privately held, clinical stage biotechnology
Continue Reading Amgen Acquires Multispecific Immunotherapy Biotech Startup TeneoBio
mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
In today’s world, e-commerce and online visibility are sine qua non for success. Businesses are willing to invest considerable sums
Continue Reading Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out
On April 29, 2021, Mountain View, California-based startup Ceribell, Inc. announced the completion of a $53 million Series C financing,
Continue Reading Ceribell Announces Completion of $53 Million Series C Financing for Portable EEG that can Diagnose Seizures in Minutes
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of
Continue Reading The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital
Continue Reading Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac.
Continue Reading The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the
Continue Reading The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I